Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

NCT05253911 · clinicaltrials.gov ↗

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: TUKYSA®

Sponsor

iOMEDICO AG

Collaborators

[object Object]